Back to Search
ROBERT CASTLEBERRY, M.D.
M.D.
Pediatric Hematology & Oncology Physician
NPI: 1124131289Individual
Specialties, Licenses & Credentials
Pediatric Hematology & Oncology PhysicianPrimary
Pediatrics — Pediatric Hematology-Oncology
Code: 2080P0207X
6008(AL)
Research & Publications (20)
PTEN deficiency is a common defect in juvenile myelomonocytic leukemia.
PMID 19010541·Leuk Res·2009
8-other
Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
PMID 18281664·J Clin Oncol·2008
4-observational
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia.
PMID 18000165·Blood·2008
8-other
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
PMID 18704922·Pediatr Blood Cancer·2008
8-other
Changing trends of research and treatment in infant neuroblastoma.
PMID 17943963·Pediatr Blood Cancer·2007
6-review
Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.
PMID 16782927·J Clin Oncol·2006
2-rct
Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study.
PMID 16735707·J Clin Oncol·2006
8-other
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
PMID 15928039·Blood·2005
4-observational
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
PMID 16314642·J Clin Oncol·2005
2-rct
Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization, and health-related behaviors from the childhood cancer survivor study.
PMID 16170159·J Clin Oncol·2005
8-other
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
PMID 16116153·J Clin Oncol·2005
4-observational
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
PMID 16116152·J Clin Oncol·2005
3-trial
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives.
PMID 16024170·Cancer Lett·2005
6-review
Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma.
PMID 15641027·Cancer·2005
3-trial
Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.
PMID 15390271·Pediatr Blood Cancer·2005
8-other
Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
PMID 15483021·J Clin Oncol·2004
3-trial
Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
PMID 15226336·J Clin Oncol·2004
3-trial
Parental exposure to medical radiation and neuroblastoma in offspring.
PMID 15130156·Paediatr Perinat Epidemiol·2004
8-other
Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study.
PMID 15020603·J Clin Oncol·2004
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1600 7TH AVE S
BIRMINGHAM, AL 35233 - Phone
- (205) 939-9285
Quick Facts
- NPI
- 1124131289
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile